Proactive - Interviews for investors

NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive shared pivotal updates with Proactive, announcing the company’s engagement of a Clinical Research Organization to conduct a Phase II clinical trial for its innovative broad-spectrum antiviral therapy. This milestone represents a significant step in advancing the therapy through the regulatory process.

The upcoming Phase II trial will evaluate the effectiveness of the therapy in treating MPox, a disease caused by the human Mpox virus that has triggered a regional pandemic in parts of Africa, including the Democratic Republic of Congo and Uganda. In 2024, the World Health Organization declared MPox a Public Health Emergency of International Concern. Currently, no approved treatments exist for infections caused by this virus.

The therapy has shown strong antiviral activity in preclinical studies, particularly against an orthopoxvirus model that serves as a critical predictor of efficacy for MPox and Smallpox. Notably, its effectiveness matched that of tecovirimat, a widely recognized antiviral, in both direct skin and lung infection models.

Dr. Diwan underscored the potential impact of this therapy in addressing a pressing global health challenge, positioning NanoViricides as a leader in developing innovative treatments for diseases caused by orthopoxviruses. With this trial, the company aims to provide a critical solution to an urgent unmet medical need.

#proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc

M2i Global CEO Alberto Rosende joined Steve Darling from Proactive to discuss the company’s response to the Executive Order "Unleashing American Energy," signed by U.S. President Donald Trump on January 20, 2025. The order aligns closely with M2i’s mission to enhance domestic critical mineral production, supporting U.S. defense sector resilience and economic growth.

Rosende highlighted that the Executive Order accelerates M2i’s ability to expand Joint Venture arrangements and critical mineral partnerships. The company is collaborating with federal facilities and lands to develop a Strategic Mineral Reserve, meeting the mandate to boost domestic production and reduce dependence on foreign supply chains.

M2i’s robust ecosystem of partners offers turnkey solutions, enabling business expansion, securing offtake agreements, and driving strategic government policies. The company collaborates with federal and state governments, universities, specialized mining firms, and NGOs to position the U.S. as a global leader in critical minerals processing.

The company’s international business model ensures that minerals are ethically sourced, adhere to stringent environmental and labor standards, and are exclusively traded with authorized countries. M2i's partnerships with allies like Australia further strengthen its framework, leveraging advanced technologies to create a strategic reserve for the U.S. defense sector, aligning with President Trump’s vision for energy and resource independence.

#proactiveinvestors #m2iglobalinc #otcqb #mtwo #SupplyChain #M2iGlobal #AlbertoRosende #StrategicMineralReserve #RecyclingEconomy #MineralsIndependence #EnergySecurity #ProactiveInvestors #MiningIndustry

Livium Ltd (ASX:LIT, OTC:LMMFF) managing director and CEO Simon Linge talks with Proactive’s Tylah Tully about the company’s latest updates, focusing on its strategic initiatives and near-term goals.

Linge highlighted Livium’s strong emphasis on scaling its battery recycling business to meet the growing influx of large-format lithium-ion batteries, positioning the company as a key player in this growing sector.

He discussed two other patented technologies, including LieNA® technology, developed in partnership with Mineral Resources, which is moving to its next phase of development.

Additionally, Livium’s battery materials technology has made progress with customer agreements and product portfolio advancements, enabling the company to scale this segment.

Linge explained how the organisation was actively pursuing funding opportunities through strategic, public and private partnerships.

On restructuring, Linge outlined the ongoing cost-saving measures and workforce changes designed to position Livium for sustainable growth through 2026.

He emphasised the company’s commitment to securing battery recycling agreements and a pipeline for large-format battery supplies, which are expected to reach 25,000 tonnes by the end of the decade.

Stay tuned for further updates on Livium’s recycling milestones, restructuring developments, and commercialisation efforts.

#ProactiveInvestors #LiviumLtd #ASX #OTC #BatteryRecycling #LithiumIonBatteries #EnergyStorage #SustainableTechnology #ASXLIT #BatteryMaterials #CircularEconomy #SimonLinge

Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Leeuwin Metals Ltd (ASX: LM1).

Leeuwin Metals has raised A$3.25 million through a two-tranche share placement priced at A$0.098 per share, reflecting an 18.3% discount to the last closing price.

The placement attracted strong interest from institutional and sophisticated investors, with contributions of approximately A$250,000 from directors and management, subject to shareholder approval.

The placement comprises two tranches: Tranche 1 raised approximately A$1.55 million, while Tranche 2 is expected to raise A$1.7 million, contingent on shareholder approval at an extraordinary general meeting scheduled for February 2025.

The funds will support exploration and drilling activities across Leeuwin’s Australian and Canadian project portfolio, working capital and placement costs.

A key focus is the Marda Gold Project in Western Australia, which Leeuwin is acquiring from Ramelius Resources. Announced in December 2024, the acquisition is anticipated to conclude in Q1 2025.

Leeuwin's management highlighted the strategic significance of the Marda acquisition, located in a renowned goldfield, as a growth opportunity for shareholders.

The funding positions the company to advance its exploration programs across its highly prospective assets.

#ProactiveInvestors #LeeuwinMetals #GoldMining #CapitalRaising #MardaGoldProject #ASXUpdate #InstitutionalInvestors #SophisticatedInvestors #GoldExploration #WesternAustralia #CanadaMining #MineralResources #SharePlacement #RameliusResources #MineralExploration #MiningProjects #CorporateUpdate #ExplorationFunding #InvestmentOpportunities #GoldFields #ASXNews

Sona Nanotech CEO David Regan joined Steve Darling from Proactive to share the publication of groundbreaking findings from the company’s pre-clinical breast cancer and melanoma efficacy studies in the prestigious scientific journal Frontiers in Immunology. This comprehensive research highlights the transformative potential of Sona’s Targeted Hyperthermia Therapy (THT) and includes critical new follow-up data on its immune-activating properties.

Sona’s proprietary technology employs patented, biocompatible gold nanorods (GNRs) to deliver precision, non-invasive hyperthermia therapy directly to cancer cells. This approach minimizes systemic toxicity, a common drawback of traditional cancer treatments. The study demonstrated that Sona’s THT induces cancer-specific cell death while triggering a robust immune response, marking a significant breakthrough in cancer immunotherapy.

Notably, the research revealed that the immune response activated by Sona’s THT is effective against cancers that are typically resistant to modern immunotherapies. This novel immunity offers a critical advantage, paving the way for new treatment possibilities in cases where conventional methods fall short.

#proactiveinvestors #sonananotechinc #cse #sona #otcqb #snanf #CancerResearch #GoldNanorods #TargetedTherapy #Biotechnology #CancerTreatment #HyperthermiaTherapy #Immunology #MedicalBreakthroughs #Nanotechnology

AOTI Inc (AIM:AOTI) CEO, president, and co-founder Dr Mike Griffiths talked with Proactive about the company’s efforts to revolutionise chronic wound care. AOTI is focused on treating conditions like diabetic foot ulcers with its unique home-based oxygen therapy, designed to promote durable healing.

Griffiths highlighted the staggering $80 billion US diabetic foot ulcer care market and shared that AOTI is well-positioned to expand within this space. He noted that AOTI’s strong clinical evidence and ability to reduce hospitalisations and amputations resonate strongly with payers and healthcare providers.

He also shared recent milestones, including the company’s expansion into six Medicaid states, its five-year renewal of the Veterans Affairs contract, and ongoing efforts to broaden its international presence. Griffiths announced the start of enrolments for the venous leg ulcer (VLU) clinical trial and discussed its significance in building high-quality evidence for AOTI's therapy.

AOTI, headquartered in the US and listed on AIM, has grown by over 30% annually for five years and Griffiths expects this growth to continue as it enters new markets like skilled nursing and long-term care. “We believe we’re in a very exciting sector, with solutions that deliver long-term outcomes,” he shared.

Visit Proactive’s YouTube channel for more videos, and don’t forget to like, subscribe, and enable notifications for updates!

#AOTI #ChronicWoundCare #DiabeticFootUlcers #MedicalTechnology #HealthcareInnovation #OxygenTherapy #Medicaid #VeteransAffairs #ClinicalTrials #MedTechGrowth

hVIVO PLC CEO Yamin 'Mo' Khan talked with Proactive's Stephen Gunnion about the company's involvement in a world-first Phase 3 human challenge trial for a pertussis (whooping cough) vaccine candidate. The trial, in partnership with ILiAD Biotechnologies, is expected to start in the second half of this year.

Khan highlighted the importance of this milestone for hVIVO, noting that it will be the company's largest challenge trial to date and its first bacterial challenge trial. The trial data aims to secure FDA marketing authorisation, marking a pivotal moment for the utility of human challenge trials in vaccine development.

According to Khan, "The goal is to get a better vaccine to patients faster. Pertussis is a severe disease, particularly for infants, and there's an urgent need for new vaccines." He further explained that hVIVO's state-of-the-art Canary Wharf facility will play a critical role in supporting this trial, equipped with expanded laboratory capabilities for bacterial analysis.

The trial comes as cases of pertussis are on the rise, increasing sixfold between 2023 and 2024. ILiAD Biotechnologies has also secured FDA fast-track status and an MHRA innovation passport for this vaccine candidate. Khan emphasised the partnership's goal of addressing this unmet medical need and delivering an effective vaccine to patients worldwide.

Visit Proactive's YouTube channel for more videos, and don’t forget to like, subscribe, and enable notifications for future updates.

#hVIVO #VaccineDevelopment #WhoopingCough #Pertussis #ClinicalTrials #FDAApproval #BiotechInnovation #Phase3Trial #HumanChallengeTrials #HealthcareResearch

Fineqia International Inc CEO Bundeep Singh Rangar talked with Proactive's Stephen Gunnion about launching the world’s first exchange-traded product (ETP) that deploys digital assets in yield-bearing decentralized finance (DeFi). Rangar explained the product's unique value, providing access to DeFi yield through a transparent, regulated security listed on the Vienna Stock Exchange.

The Fineqia FTSE Cardano Enhanced Yield ETN (AV:YADA) is based on the Cardano network, a top ten cryptocurrency valued at over $35 billion, and allows investors to participate in DeFi activities such as borrowing, lending, and validating transactions, which generate fees. Unlike traditional ETFs and ETNs, Fineqia's product reinvests 80% of these yields back to investors, making it a truly innovative approach.

Rangar highlighted the importance of partnering with FTSE Russell, a subsidiary of the London Stock Exchange, to ensure robust pricing data for this groundbreaking product. He added, "This is an icebreaker for what we want to do in the industry... We’re about being innovative and different."

This collaboration sets a milestone for the ETP industry by combining blockchain technology and traditional finance, giving fund managers and retail investors easy access to decentralized finance through a familiar financial instrument.

Visit Proactive's YouTube channel for more videos like this one, and don’t forget to give the video a like, subscribe to the channel, and enable notifications for updates!

#Fineqia #DeFi #CryptoETP #DecentralizedFinance #Cardano #DigitalAssets #ETN #CryptoInvesting #Blockchain #FTSERussell

GoviEx Uranium Inc (TSX-V:GXU, OTCQX:GVXXF) CEO Daniel Major discussed the just-released feasibility study for the Mutanga Uranium project in Zambia with Proactive's Stephen Gunnion. Major highlighted that the study outlines solid project economics, including a net present value (NPV) of $243.00 million and an internal rate of return (IRR) of 20.8% at a uranium price of $90.00 per pound. He described Mutanga as a straightforward open-pit project benefiting from local infrastructure and low technical risks.

The company plans to produce 2.20 million pounds of uranium annually over a 12-year lifespan. Major emphasised the potential for resource expansion from nearby satellite deposits, which could further enhance the project’s value. Additionally, he outlined the global uranium market dynamics, noting a deficit in supply and growing demand driven by new reactors, life extensions for existing reactors, and advancements in small modular reactors (SMRs).

Looking ahead, GoviEx is targeting project construction by 2028 and is actively seeking debt financing and offtake agreements to move forward. Major said, "We’re already sharing our feasibility study with utilities to ensure we meet their requirements."

Watch the full interview to learn more about GoviEx’s strategy for meeting global uranium demand. Don’t forget to like the video, subscribe to Proactive’s YouTube channel, and enable notifications for future updates!

#GoviExUranium #MutangaProject #UraniumMining #ZambiaResources #EnergyDemand #UraniumFeasibility #LowRiskMining #GlobalEnergy #NuclearEnergy #SmallModularReactors

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO Andrew Newland talked with Proactive's Stephen Gunnion about groundbreaking research using the Parsortix system. This system has enabled significant advancements in cancer research, including a recent study published in Nature Medicine that explores stopping the metastatic spread of cancer.

Newland explained how Parsortix helps identify and analyse circulating tumour cell clusters, which are critical to cancer progression. He highlighted research led by Professor Nicola Aceto at the Cancer Metastasis Laboratory in Zurich, where they discovered that FDA-approved cardiac drugs could break these clusters into individual cells. In mice and breast cancer patients, this approach showed potential to halt cancer progression.

The CEO emphasised Parsortix's central role in identifying patients and monitoring treatment efficacy, predicting global interest and demand for the system. He also discussed ANGLE's broader work with cancer drug developers, including collaborations with companies like AstraZeneca and Eisai, to unlock new approaches to managing cancer.

Newland concluded with optimism, envisioning a future where cancer could become a manageable condition, similar to how HIV/AIDS is now controlled.

Discover more about this transformative research and ANGLE PLC’s contributions. Like this video, subscribe to Proactive’s channel, and enable notifications for future updates!"

#ANGLEPLC #Parsortix #CancerResearch #CancerBreakthrough #Oncology #Metastasis #CirculatingTumorCells #MedicalInnovation #NatureMedicine #CancerAwareness